Regulatory Headwinds Threaten Hims & Hers’ Growth Trajectory

Investors in the telemedicine platform Hims & Hers are facing a complex investment landscape. While the company continues to demonstrate impressive operational growth, escalating regulatory challenges are creating significant uncertainty about its future prospects.

The company’s third-quarter 2025 results revealed substantial operational progress. Hims & Hers expanded its subscriber base by 21% to reach 2.47 million users, while average revenue per user climbed 19% to $80 monthly. Total revenue surged 49% to $599 million, demonstrating strong market demand for the company’s services.

However, this growth story faces potential disruption from regulatory pressures. In September 2025, the U.S. Food and Drug Administration issued warning letters to approximately 100 marketers, including Hims & Hers, concerning what Read more...